ATHA Energy Successfully Completes Diamond Drilling at RIB North Discovery, Expanding Strike Length To 3.4 Km, And Identifies a Higher-Grade Sub Zone: Results Include RIBN-DD-023 Intersecting 19.5 M Of Composite Uranium Mineralization With 2.0 M Of High-GradeAccesswire · Oct 7, 2026
Athena Announces Amalgamation of Subsidiary to Streamline OperationsNewsfile Corp · Sep 11, 2026
Athena Appoints Fred Leigh to Board of DirectorsNewsfile Corp · Sep 8, 2026
ATHA Energy Announces Additional Results from Rib North Discovery Expanding Continuity of Mineralization from 300 metres to 1.45 Kilometres – Results Include RIBN-DD-011 Intersecting 20 m of Composite Uranium Min Including 1.3 m of High-GradeAccesswire · Sep 8, 2026
Athena Provides Drilling Update from Excelsior Springs, NevadaNewsfile Corp · Sep 1, 2026
ATHA Energy Provides Board of Directors UpdateAccesswire · Aug 31, 2026Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease.